Bristol Myers CVR Dealt Blow as Key Drug Faces Approval Hurdle

(Bloomberg) -- Bristol-Myers Squibb Co.’s announcement that U.S. regulators weren’t able to meet a targeted decision deadline for a lymphoma cell therapy dealt a blow to investors as hopes for a de...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.